{"id":"https://openalex.org/W4362494955","doi":"https://doi.org/10.1158/1535-7163.c.6537612","title":"Data from Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma","display_name":"Data from Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362494955","doi":"https://doi.org/10.1158/1535-7163.c.6537612"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.c.6537612","doi":"https://doi.org/10.1158/1535-7163.c.6537612","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.c.6537612","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1535-7163.c.6537612","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100346105","display_name":"Jin Wang","orcid":"https://orcid.org/0000-0001-5420-5704","observed_orcids":["https://orcid.org/0000-0001-5420-5704"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100410492","display_name":"Jianjun Chen","orcid":"https://orcid.org/0000-0001-5668-6572","observed_orcids":["https://orcid.org/0000-0001-5668-6572"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jianjun Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016676195","display_name":"Duane D. Miller","orcid":"https://orcid.org/0000-0002-6093-0985","observed_orcids":["https://orcid.org/0000-0002-6093-0985"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Duane D. Miller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5100318325","display_name":"W\u011bi Li","orcid":"https://orcid.org/0000-0002-9522-4474","observed_orcids":["https://orcid.org/0000-0002-9522-4474","https://orcid.org/0000-0003-4136-3409","https://orcid.org/0009-0009-9141-6389"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wei Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.925000011920929},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8830000162124634},{"id":"https://openalex.org/keywords/braf-v600e-melanoma","display_name":"BRAF V600E melanoma","score":0.925000011920929},{"id":"https://openalex.org/keywords/tubulin-polymerization-inhibitors","display_name":"tubulin polymerization inhibitors","score":0.9599999785423279},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8920000195503235},{"id":"https://openalex.org/keywords/g2-m-cell-cycle-arrest","display_name":"G2/M cell cycle arrest","score":0.7699999809265137},{"id":"https://openalex.org/keywords/akt-signaling","display_name":"Akt signaling","score":0.718999981880188},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.9559999704360962},{"id":"https://openalex.org/keywords/raf-mek-erk-pathway","display_name":"Raf/MEK/ERK pathway","score":0.8999999761581421},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6700000166893005},{"id":"https://openalex.org/keywords/synergistic-drug-combination","display_name":"synergistic drug combination","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.995317816734314},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6819061040878296},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5988298654556274},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.540624737739563},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.47570639848709106},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.4666113257408142},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.42867714166641235},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.41636577248573303},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.40285593271255493},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3757941722869873},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35839343070983887},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3560064435005188},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.29546216130256653},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.23256739974021912},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1263141632080078},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09227240085601807}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.c.6537612","doi":"https://doi.org/10.1158/1535-7163.c.6537612","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.c.6537612","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.c.6537612","doi":"https://doi.org/10.1158/1535-7163.c.6537612","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.c.6537612","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2140822400","https://openalex.org/W1554652277","https://openalex.org/W2472423380","https://openalex.org/W3142095748","https://openalex.org/W2922270413","https://openalex.org/W2563532854","https://openalex.org/W2996253303","https://openalex.org/W2254543840","https://openalex.org/W2171108516","https://openalex.org/W2895562037"],"abstract_inverted_index":{"Abstract":[0],"Acquired":[1],"clinical":[2],"resistance":[3,117],"to":[4,33,40,96,118,236,250],"vemurafenib,":[5],"a":[6,48,54,232],"selective":[7],"BRAFV600E":[8],"inhibitor,":[9],"arises":[10],"frequently":[11],"after":[12],"short-term":[13],"chemotherapy.":[14],"Because":[15],"inhibitions":[16],"of":[17,79,132,142,178,202,212],"targets":[18],"in":[19,24,149,157,209,220,225,242],"the":[20,41,74,106,122,129,140,150,162,171,176,184,200,221,239],"RAF\u2013MEK\u2013ERK":[21],"pathway":[22],"result":[23],"G0\u2013G1":[25],"cell-cycle":[26,36],"arrest,":[27],"vemurafenib-resistant":[28,163,222],"cancer":[29],"cells":[30,62,148],"are":[31],"expected":[32],"escape":[34],"this":[35,69],"arrest":[37],"and":[38,63,85,91,99,120,144,153,161,180,187,191],"progress":[39],"subsequent":[42],"G2\u2013M":[43,55],"phase.":[44],"We":[45,108],"hypothesized":[46],"that":[47,139,170],"combined":[49],"therapy":[50],"using":[51],"vemurafenib":[52,65,86,119,134,145,213,252],"with":[53,114,214,244],"phase":[56],"blocking":[57],"agent":[58],"will":[59],"trap":[60],"resistant":[61,249],"overcome":[64],"resistance.":[66,135],"To":[67],"test":[68],"hypothesis,":[70],"we":[71,127],"first":[72],"determined":[73],"combination":[75,141,172,234],"index":[76],"(CI)":[77],"values":[78],"our":[80],"novel":[81],"tubulin":[82],"inhibitor":[83],"ABI-274":[84,143,215],"on":[87,199],"parental":[88,159],"human":[89],"A375":[90,160],"MDA-MB-435":[92],"melanoma":[93,245],"cell":[94],"lines":[95],"be":[97],"0.32":[98],"0.1,":[100],"respectively,":[101],"suggesting":[102],"strong":[103,123,217],"synergy":[104],"for":[105],"combination.":[107],"then":[109],"developed":[110],"an":[111],"A375RF21":[112,164],"subline":[113],"significant":[115,197],"acquired":[116],"confirmed":[121,138],"synergistic":[124,218],"effect.":[125],"Next,":[126],"studied":[128],"potential":[130],"mechanisms":[131],"overcoming":[133],"Flow":[136],"cytometry":[137],"synergistically":[146],"arrested":[147],"G1\u2013G2\u2013M":[151],"phase,":[152],"significantly":[154,237],"increased":[155,188],"apoptosis":[156,185],"both":[158],"cells.":[165],"Western":[166],"blot":[167],"analysis":[168],"revealed":[169],"treatment":[173],"effectively":[174],"reduced":[175],"level":[177,201],"phosphorylated":[179],"total":[181],"AKT,":[182],"activated":[183],"cascade,":[186],"cleaved":[189,192],"caspase-3":[190],"PARP,":[193],"but":[194],"had":[195],"no":[196],"influence":[198],"extracellular":[203],"signal\u2013regulated":[204],"kinase":[205],"(ERK)":[206],"phosphorylation.":[207],"Finally,":[208],"vivo":[210],"coadministration":[211],"showed":[216],"efficacy":[219],"xenograft":[223],"model":[224],"nude":[226],"mice.":[227],"Overall,":[228],"these":[229],"results":[230],"offer":[231],"rational":[233],"strategy":[235],"enhance":[238],"therapeutic":[240],"benefit":[241],"patients":[243],"who":[246],"inevitably":[247],"become":[248],"current":[251],"therapy.":[253],"Mol":[254],"Cancer":[255],"Ther;":[256],"13(1);":[257],"16\u201326.":[258],"\u00a92013":[259],"AACR.":[260]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}